Healthcare Trust of America’s (HTA) performance expectations in 2018 have been reflected in its analyst ratings. Analysts gave HTA a mean price target of $33.38, implying a significant ~26.0% rise from its current level of $26.30. It has a market capitalization of ~$5.5 billion.
In February 2018, ten of 12 analysts covering the stock gave it “buy” or “strong buy” ratings, and the remaining two analysts gave it “hold” ratings. Compared to January 2018, the number of Healthcare Trust of America “strong buy” and “buy” ratings have been constant.
Healthcare Trust of America’s peer ratings
Among Healthcare Trust of America’s major alternative peers, HCP (HCP) garnered “buy” or “strong buy” ratings from four of 20 analysts. It earned “hold” ratings from 15 analysts, and one analyst gave it a “sell” rating. The target price for HCP is $26.66 while the current price is $22.68.
Five of twenty-two analysts gave Welltower (HCN) “buy” or “strong buy” ratings, 14 analysts gave it “hold” ratings, and the remaining three analysts gave it “sell” ratings. The target price for HCN is $67.75, up from the current level of $55.79.
Two of 20 analysts gave Ventas (VTR) “buy” or “strong buy” ratings, 14 analysts gave it “hold” ratings, and the remaining four analysts gave it “underperform” ratings. The target price for VTR is $56.50, up from the current level $51.39.
Investors looking for exposure to the healthcare real estate industry can consider REIT ETFs. HTA comprises 0.69% of the Vanguard Real Estate Index ETF (VNQ).